The ALS Emergency Treatment Fund (ALS-ETF) and Denovo Biomarkers (Denovo) have entered into partnership to explore using Denovo's technology to identify potential responder groups for drugs that are being studied in patients suffering from Amyotrophic Lateral Sclerosis (ALS).
This personalized medicine approach may accelerate drug development in ALS and other life-threatening disorders.
The partnership will incorporate Denovo's pharmacogenomic technology into the analysis of biological samples obtained from expanded access programs (EAP's) that ALS-ETF sponsors.
The partners seek to identify patient subsets for the conduct of subsequent trials by identifying genomic biomarkers that correlate with patients' responsiveness to the treatment.
ALS-ETF managing director Jess Rabourn said that the relationship with Denovo may accelerate the development of drugs for ALS and may help the company provide useful information for patients and physicians.
"This partnership leverages the mission of ALS-ETF and the broad utility of our platform," Rabourn added.
ALS is a fatal disease that compromises patients' ability to move, speak, swallow and breathe.
